Site is Being Upgraded

Probiotic-based adjunctive therapy for Malaria: Probiotic Lactobacillus reuteri (DSM 17938 and ATCC PTA 5289) increases Ferroportin expression, decreases intracellular iron accumulation, inhibits cellular damage, prevents hemolysis, and inhibits malaria infection, via upregulation of its target gene, 5/December/2018, 9.35 pm

Probiotics as anti-infective agents:  Probiotics-based adjunct therapy for viral and bacterial infections: Probiotic Lactobacillus Rhamnosus GG CGMCC 1.2134 (LGG) inhibits Hepatitis-B/C, Dengue, Zika, Ebola, HIV-1, Mtb, Malaria, CMV, Influenza H1NI1,  respiratory syncytial,  Sindbis, and SFV viruses by increasing the Levels of the antiviral Proteins IFITM3, & Interferon-stimulated gene, 5/December/2018, 2.40 pm
December 5, 2018
Probiotic-based therapy for Metastatic cancers: Probiotic Lactobacillus rhamnosus decreases the expression of metastasis promoters ZBTB2 and PPM1F, inhibits cell cycle progression, and suppresses migration, invasion, and metastasis of cancer cells, via up regulation of its target gene, 5/December/2018, 10.44 pm
December 5, 2018
Show all

Introduction: What they say:

A study from the Section on Human Iron Metabolism, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD 20892, USA shows that “Erythrocytic ferroportin reduces intracellular iron accumulation, hemolysis, and malaria risk.” This study was published, in the 30 March 2018 issue of the journal Science (one of the best journals in science with an impact factor of 37+), by Prof. Rouault, Zhang, and others.


What we say:

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Probiotic-based adjunctive therapy for Malaria: Probiotic Lactobacillus reuteri (DSM 17938 and ATCC PTA 5289) increases Ferroportin expression, decreases intracellular iron accumulation, inhibits cellular damage, prevents hemolysis, and inhibits malaria infection, via upregulation of its target gene


What is known?

A number of studies suggests that malarial parasite disrupts iron regulation in RBCs of humans and thereby causes anemia. Unfortunately, iron supplementation therapy exacerbates malarial infections, rather than attenuating malarial infections. However, the molecular basis of this anomaly is far from clear.

Prof. Rouault’s research team has recently shown that: (1)iron transporter ferroportin (FPN) is present in abundant amounts in RBCs; (2) iron supplementation decreases ferroportin’s activity; (3) knock-out of ferroportin gene in erythroid cells: (a) increases the levels of intracellular iron; (b) augments cellular damage; (c) accelerates hemolysis; and (d) increases mortality in malaria-infected mice; (5) hepcidin-induced degradation of ferroportin is prevented by mutation (Q248H) in ferroportin  gene and this mutation is common in African population (explaining why considerable no. of people in African populations are resistant to malarial infection). Together, this study suggests that increasing the expression of ferroportin in precursors of RBCs may inhibit the accumulation of intracellular iron, decrease oxidative stress, and attenuate malarial infection.


From Significance of the study to Public health relevance:

Given that: (1) 214 million new cases of malaria had been reported in 2015; (2) nearly 438,000 people out of 214 million people who were infected with Malaria had died in 2015; (3) malaria has the potential to affect nearly half the global population; (4) molecular pathways involved and the mechanism of development of drug-resistant malaria are far from understood; (4) treating drug-resistant malaria is still a daunting task; (5) millions of deaths occur due to malaria every year; (6) out of the 125 million international travellers who visit countries, such as Ivory Coast, Angola, Burkina Faso, Burkina Faso, Mozambique and Mali, more than 30, 000 contract the disease; (7) most of the malaria cases are registered in countries, such as sub-Saharan Africa—that cannot afford high-cost required for the treatment of drug-resistant malaria—compared to developed countries, such as US (10,000 malaria cases per year) and UK (1,500 malaria cases/year), (8) humans could not mount immunity against blood stage-malaria; and prevent re-infections; and (9) billions of dollars are being spent each year globally for the treatment of malaria, there is an urgent need to find: (i) a way to inhibit drug-resistant malaria; and (ii) a side-effect-free-Natural product-based drug that prevents relapse/recurrence of blood-stage/drug-resistant Malaria.


From Research Findings to Therapeutic opportunity:

This study suggests, for the first time, to the best of our knowledge,  that  Probiotic Lactobacillus reuteri may aid in the treatment of malaria infection. Probiotic Lactobacillus reuteri (DSM 17938 and ATCC PTA 5289), by increasing the expression of its target gene, it may: (1) increase iron transporter Ferroportin expression; (2) decrease the negative regulator of iron transporter Ferroportin, hepcidin expression; (3) decrease intracellular iron accumulation; (4) decrease oxidative stress; (5) inhibit cellular damage; (5) prevent hemolysis; and (6) attenuate malarial infection. Together, pharmacological formulations encompassing “Probiotic Lactobacillus reuteri (DSM 17938 and ATCC PTA 5289), either alone or in combination with other anti-malarial drugs, “ may be used to treat malaria.

Figure 1. Mechanistic insights into how Probiotic Lactobacillus reuteri (DSM 17938 and ATCC PTA 5289) may attenuate malaria infection. Probiotic Lactobacillus reuteri (DSM 17938 and ATCC PTA 5289), by increasing the expression of its target gene, it may increase ferroportin levels and decrease intracellular iron accumulation. Thereby, it may promote malarial parasite clearance.

Figure 2.  Probiotic Lactobacillus reuteri (DSM 17938 and ATCC PTA 5289)  functions as an anti-malarial agent.


Details of the research findings:

Undisclosed mechanistic information: How  Probiotic Lactobacillus reuteri (DSM 17938 and ATCC PTA 5289) increases ferroportin expression

Idea Proposed/Formulated by: Dr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Amount: $500#

# Research cooperation


References:

Web: http://genomediscovery.org or http://newbioideas.com

Citation: Boominathan, L., Probiotic-based adjunctive therapy for Malaria: Probiotic Lactobacillus reuteri (DSM 17938 and ATCC PTA 5289) increases Ferroportin expression, decreases intracellular iron accumulation, inhibits cellular damage, prevents hemolysis, and inhibits malaria infection, via upregulation of its target gene, 5/December/2018, 9.35 pm, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite drop us a line at info@genomediscovery.org

Comments are closed.